In the Claims

Claims 1-46 (Canceled).

Claim 47 (Currently Amended): A method for stimulation of cytotoxicity by NK cells, comprising:

contacting said NK cells with an amount of antibody ~~or a binding fragment thereof~~ effective to stimulate the activity of said NK cells, said antibody ~~which~~ specifically ~~binds~~ binding to a polypeptide ~~having at least an~~comprising the amino acid sequence of SEQ ID NO:2~~, effective to stimulate their cytotoxicity~~.

Claims 48-63 (Canceled).

Claim 64 (Previously Presented): The method according to claim 47, wherein said antibody is a polyclonal antibody.

Claim 65 (Previously Presented): The method according to claim 47, wherein said antibody is a monoclonal antibody.

Claim 66 (Previously Presented): The method according to claim 47, wherein said antibody is a humanized mouse monoclonal antibody.

Claim 67 (Previously Presented): The method according to claim 47, wherein said antibody is an antibody of human origin.

Claim 68 (Currently Amended): The method according to claim 65, wherein said monoclonal antibody is produced by ~~hybridoma I-2576~~the hybridoma having CNCM Registration Number I-2576.

Claims 69-73 (Canceled)

Claim 74 (New): A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody effective to stimulate the activity of said NK cells, said antibody specifically binding to a polypeptide comprising the amino acid sequence of: SEQ ID NO: 4 or SEQ ID NO: 7.

Claim 75 (New): The method according to claim 74, wherein said antibody is a polyclonal antibody.

Claim 76 (New): The method according to claim 74, wherein said antibody is a monoclonal antibody.

Claim 77 (New): The method according to claim 74, wherein said antibody is a humanized mouse monoclonal antibody.

Claim 78 (New): The method according to claim 74, wherein said antibody is an antibody of human origin.

Claim 79 (New): The method according to claim 76, wherein said monoclonal antibody is produced by the hybridoma having CNCM Registration Number I-2576.

Claim 80 (New): The method according to claim 74, wherein said antibody specifically binds to a polypeptide comprising SEQ ID NO: 4.

Claim 81 (New): The method according to claim 74, wherein said antibody specifically binds to a polypeptide comprising SEQ ID NO: 7.

Claim 82 (New): The method according to claim 74, wherein said antibody specifically binds to a polypeptide consisting of SEQ ID NO: 4.

Claim 83 (New): The method according to claim 74, wherein said antibody specifically binds to a polypeptide consisting of SEQ ID NO: 7.

Claim 84 (New): A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody having the binding specificity of the antibody produced by the hybridoma having CNCM Registration Number I-2576, said antibody having the ability to stimulate the cytotoxicity of said NK cells.

Claim 85 (New): A method of binding NK cells to antibody comprising contacting said NK cells with an antibody, or an immunoreactive fragment thereof, that specifically binds to the NKp30 polypeptide (SEQ ID NO: 2) or an immunogenic fragment thereof.

Claim 86 (New): The method according to claim 85, wherein said antibody is a polyclonal antibody.

Claim 87 (New): The method according to claim 85, wherein said antibody is a monoclonal antibody.

Claim 88 (New): The method according to claim 85, wherein said antibody is a humanized mouse monoclonal antibody.

Claim 89 (New): The method according to claim 85, wherein said antibody is an antibody of human origin.

Claim 90 (New): The method according to claim 85, wherein said monoclonal antibody is produced by hybridoma having CNCM Registration Number I-2576.

Claim 91 (New): The method according to claim 85, wherein said antibody or immunoreactive fragment thereof is coupled to a label.

Claim 92 (New): The method according to claim 91, wherein said label is a fluorescent label.

Claim 93 (New): The method according to claim 92, wherein said antibody or immunoreactive fragment thereof is attached to a solid support.

Claim 94 (New): The method according to claim 93, wherein said solid support is selected from the group consisting of paramagnetic microspheres, submicroscopic microbeads, semi-permeable substrate consisting of an array of hollow fibers, and dense particles.

Claim 95 (New): The method according to claim 85, wherein said NK cells are contacted with immunoreactive fragment of an antibody that specifically binds to the NKp30 polypeptide (SEQ ID NO: 2) or an immunogenic fragment thereof.

Claim 96 (New): The method according to claim 47, wherein said antibody cross-links NKp30 (SEQ ID NO: 2).